XstalBio launches CentuRecon
To accelerate the delivery of biologic drugs at high concentration
XstalBio has launched CentuRecon, a patented reconstitution technology, which could revolutionise the preparation of high concentration protein solutions from dry powders and make delivery faster and safer.
Biologic drugs such as monoclonal antibodies are a major growth area for the pharmaceutical industry but their delivery by subcutaneous administration is challenging, says the Glasgow, Scotland-based firm.
CentuRecon enables dry formulations of therapeutic proteins to be prepared for injection at high concentration in minutes and produces foam-free solutions that maximise the deliverable dose.
The reconstitution technology works with standard lyophilised formulations and diluents and with normal vials, cartridges or dual-chamber syringes. It is said to be particularly beneficial for very high concentration and/or viscous solutions that may need to be delivered with injection devices.
The firm says doctors will find CentuRecon straightforward and cost-effective to implement and patients will benefit from fewer injections and shorter visits. Further developments are expected to make self-administration simpler and more convenient.
‘We believe CentuRecon is a game-changing technology; uniquely it provides a rapid, safe and reproducible method for preparing very high concentration protein solutions from dry powder formulations,’ said XstalBio’s R&D Director, Barry Moore.
‘We believe it will open up new clinical opportunities for biologics and become the reconstitution method of choice for R&D scientists.’
